Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

How to Reconstitute Cerebrolysin

Cerebrolysin is a multimodal neuropeptide preparation supplied as a sterile solution for laboratory research. This page covers its identifiers, the pathways studied, and the reconstitution and handling considerations rep

peptides-pro Editorial

Cerebrolysin is a multimodal neuropeptide preparation derived from porcine brain, supplied as a sterile solution for laboratory research use. It is not a single molecular entity: the evidence block does not provide a sequence, formula, or molecular weight, and none should be assumed. The preparation is studied as an adjunct in models of ischemic stroke, reperfusion injury, and neurorehabilitation, and in in vitro assays of cerebral endothelial cell function.

The mechanistic work described in the evidence centres on neuroprotection and neuroplasticity, with in vitro data pointing to tight-junction and metabolic protein cargo in exosomes released by cerebral endothelial cells [4].

Research Studies

Cerebrolysin and extended-window endovascular thrombectomy in acute ischemic stroke

Acute ischemic stroke caused by blockage of a large brain artery can lead to severe disability. Endovascular thrombectomy is a catheter-based procedure used to remove the blood clot and restore blood flow. It can benefit selected patients treated 6 to 24 hours after stroke onset, but some patients remain disabled even when the blocked artery is successfully reopened. Ongoing injury to brain tissue, small blood vessels, and the blood-brain barrier may contribute to this incomplete recovery [1].

A multicenter randomized clinical trial is evaluating whether Cerebrolysin, given after successful extended-window endovascular thrombectomy, can reduce brain tissue injury and support recovery [1]. This is an ongoing trial; no outcome data are reported in the evidence block.

Cerebrolysin and adjunctive therapy following mechanical thrombectomy for basilar artery occlusion

Basilar artery occlusion is an uncommon yet devastating cause of posterior circulation stroke, frequently resulting in severe disability or death despite successful reperfusion. A case report described a 67-year-old woman with multiple vascular risk factors who presented with acute basilar artery occlusion and was treated with intravenous thrombolysis followed by successful mechanical thrombectomy (Thrombolysis in Cerebral Infarction grade 3), with adjunctive Cerebrolysin therapy administered subsequently. Rapid neurological improvement was observed within 24 hours, with the National Institutes of Health Stroke Scale score decreasing from 7 to 2, followed by complete neurological recovery (NIHSS 0) [2].

This is a single case report; it does not establish efficacy and cannot be generalised to other patients.

Cerebrolysin and speech-language therapy in post-stroke Wernicke's aphasia

Post-stroke aphasia is a debilitating condition affecting approximately one-third of stroke survivors, profoundly impairing communication, social participation, and quality of life. While speech-language therapy remains the standard of care, pharmacological agents such as Cerebrolysin may enhance recovery through neuroprotection and neuroplasticity. A case report described a 38-year-old female lawyer who developed acute Wernicke's aphasia and right-sided hemiparesis following an ischemic stroke. Despite timely thrombolysis and mechanical thrombectomy, she experienced significant neurological deficits. Early multidisciplinary rehabilitation, combined with a 10-day course of Cerebrolysin, was associated with improvement [3].

This is a single case report; it does not establish efficacy and cannot be generalised to other patients.

Cerebrolysin and cerebral endothelial cell permeability in vitro

Cerebrolysin has a salutary effect on impaired cerebral endothelial cell permeability. Using an in vitro endothelial permeability assay, one study tested the hypothesis that exosomes released by Cerebrolysin-treated cerebral endothelial cells (Cerebro-Exos) have a robust therapeutic effect on dysfunctional cerebral endothelial cells. Stoichiometric analysis showed marked differences in cargo profiles between Cerebro-Exos and exosomes derived from cerebral endothelial cells without Cerebrolysin treatment (Naïve-Exos), in which Cerebro-Exos were highly enriched with metabolic and tight junction related proteins compared to Naïve-Exos. Cerebro-Exos had a superior effect compared to Naïve-Exos on restoring cerebral endothelial cell integrity impaired by fibrin and tissue plasminogen activator [4].

This finding is in vitro only. It does not demonstrate an effect in animals or humans.

Cerebrolysin and neuropathic pain, blood-spinal cord barrier breakdown, and cord pathology following nanoparticle intoxication

A retraction note concerns a study that had reported that Cerebrolysin attenuates exacerbation of neuropathic pain, blood-spinal cord barrier breakdown, and cord pathology following chronic intoxication of engineered Ag, Cu or Al (50-60 nm) nanoparticles [5]. The evidence block provides only the retraction note; the original findings are not available here and should not be relied upon.

Cerebrolysin combined with speech therapy in nonfluent aphasia recovery after ischemic stroke

A conference abstract reports a meta-analysis of the effect of Cerebrolysin combined with speech therapy on nonfluent aphasia recovery after ischemic stroke [6]. The evidence block provides only the abstract citation; the findings are not available here.

Cerebrolysin as an add-on in virtual reality neurorhehabilitation in acute stroke

A conference abstract reports on virtual reality neurorhehabilitation in acute stroke patients and the add-on effect of Cerebrolysin [7]. The evidence block provides only the abstract citation; the findings are not available here.

Cerebrolysin after endovascular thrombectomy: 12-month functional outcomes

A conference abstract reports 12-month functional outcomes in a propensity-matched cohort of patients who received Cerebrolysin after endovascular thrombectomy in stroke [8]. The evidence block provides only the abstract citation; the findings are not available here.

Cerebrolysin after tenecteplase and mechanical thrombectomy: very early short-course use

A case report describes very early short-course Cerebrolysin after tenecteplase and mechanical thrombectomy. Despite high recanalization rates with mechanical thrombectomy, large-vessel occlusion stroke results in death or dependency in over half of patients. Cerebrolysin, a multimodal neuropeptide preparation, may attenuate ischemia-reperfusion injury and support early neurorehabilitation. The report describes an 88-year-old woman [9].

This is a single case report; it does not establish efficacy and cannot be generalised to other patients.

Retracted studies involving Cerebrolysin

Several studies involving Cerebrolysin have been retracted. These include a regional comparison of the neurogenic effects of CNTF-derived peptides and Cerebrolysin in AβPP transgenic mice [10], a study of timed release of Cerebrolysin using drug-loaded titanate nanospheres in a Parkinson's disease model [11], and a study of neurotrophic effects of Cerebrolysin in the Mecp2308/Y transgenic model of Rett syndrome [12]. The evidence block provides only the retraction notes; the original findings are not available here and should not be relied upon.

Reconstitution and handling

The evidence block does not describe a reconstitution procedure, diluent, or storage condition for Cerebrolysin. It is supplied as a sterile solution for laboratory research use. No reconstitution protocol can be derived from the evidence provided, and none is offered here.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp